Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Mesothelioma, Malignant 2Melanoma 2Carcinoma 2Adult Solid Neoplasm 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Solid Neoplasm 1Seminoma 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteolysis 1Neoplasm Metastasis 1Multiple Myeloma 1Malignant Solid Tumour 1Liver Neoplasms 1Hypercalcemia 1

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Geriatric Assessment 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Neoplasm × ARQ 197 × Clear all
NCT01749384 2017-10-12

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡